FDA Approves Moderna's First mRNA Flu Vaccine After Initial Refusal
The Story
The Food and Drug Administration has approved Moderna's messenger RNA (mRNA) flu vaccine, marking the first time an mRNA vaccine for influenza has received authorization. This approval follows an initial refusal by the FDA to review the vaccine. The new vaccine utilizes mRNA technology, similar to that used in some COVID-19 vaccines, to prompt an immune response against influenza viruses. This development is seen as an advancement for public health, offering a new approach to flu prevention. The flu vaccine is intended to protect against influenza, a respiratory illness that can cause severe illness and death, particularly in older adults. The mRNA technology aims to provide a more effective or faster-acting protection compared to traditional flu vaccines. Further details on the vaccine's performance and availability are expected as it moves towards wider distribution. The approval signifies a step forward in the application of mRNA technology beyond its initial use in combating the COVID-19 pandemic.
The Spread
What they agree on
- The Food and Drug Administration approved Moderna's mRNA flu vaccine.
- This is the first mRNA flu vaccine to be approved.
- Moderna developed the vaccine.
- The FDA had an initial refusal to review the vaccine before approving it.
Where they split
- Some sources emphasize the 'breakthrough' nature of the approval for public health and the administration.
- Other sources highlight the higher injury rate of the mRNA flu vaccine compared to standard jabs.
- Coverage varies in its discussion of the potential for mRNA technology to move beyond vaccines.
- Some outlets frame the approval as a return of the 'rubber stamp' for the FDA.